Baidu
map

2015 内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(上海)

2015-12-20 中华医学会内镜学分会 中华消化内镜杂志.2015,32(12):794-799.

中华医学会消化内镜学分会与中国医师协会胰腺病专业委员会于2015 年10 月在上海组织召开了“ERCP 术后胰腺炎药物预防专家共识研讨会”,经与会专家充分讨论后共同制定了本共识意见,供广大医师在临床实践中参考借鉴,并提出进一步的修改意见。

中文标题:

2015 内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(上海)

发布日期:

2015-12-20

简要介绍:

内镜下逆行胰胆管造影术( ERCP) 是胰腺和胆道疾病的重要诊治手段,随着内镜技术的发展,ERCP的临床应用范围日趋广泛,已经成为胆胰疾病内镜微创诊治的标准方法。 


ERCP术后胰腺炎(PEP)是ERCP最常见的并发症, 发生率为5%左右,多为轻中度,少数为重度,严重时甚至可导致死亡,因此如何预防PEP是临床研究的热点课题,其中针对PEP 的预防药物研究繁多,但结论不甚一致,临床上亦无统一的PEP药物预防规范。 
 
为此中华医学会消化内镜学分会与中国医师协会胰腺病专业委员会于2015年10月在上海组织召开了“ERCP术后胰腺炎药物预防专家共识研讨会”,经与会专家充分讨论后共同制定了本共识意见,供广大医师在临床实践中参考借鉴,并提出进一步的修改意见。

制定者:
中华医学会内镜学分会(CSDE,Chinese Society of Digestive Endoscopy)
中国医师协会胰腺病专业委员会

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=121945, encodeId=744412194573, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121946, encodeId=ac7e1219464a, content=继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113387, encodeId=c3fe11338eb8, content=学习了!谢谢?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Thu Sep 08 03:58:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-11 doctorJiangchao

    继续学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=121945, encodeId=744412194573, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121946, encodeId=ac7e1219464a, content=继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113387, encodeId=c3fe11338eb8, content=学习了!谢谢?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Thu Sep 08 03:58:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-11 doctorJiangchao

    继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=121945, encodeId=744412194573, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121946, encodeId=ac7e1219464a, content=继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:55:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113387, encodeId=c3fe11338eb8, content=学习了!谢谢?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Thu Sep 08 03:58:00 CST 2016, time=2016-09-08, status=1, ipAttribution=)]
    2016-09-08 zibozhouping

    学习了!谢谢?

    0

Baidu
map
Baidu
map
Baidu
map